Frequency Limitations for Darbepoetin Alfa (trade name Aranesp) For Treatment Of Anemia In End Stage Renal Disease (ESRD) Patients On Dialysis.
We are making changes to reflect billing policy for Darbepoetin Alfa (Aranesp) and Epoetin Alfa (EPO).
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: March 05, 2004
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.